Transthyretin Amyloid Cardiomyopathy Clinical Trials

11 recruitingLast updated: June 18, 2026

There are 11 actively recruiting transthyretin amyloid cardiomyopathy clinical trials across 23 countries. Studies span Not Applicable, Phase 1, Phase 3, Phase 4. Top locations include Bruges, Belgium, Groningen, Netherlands, Berlin, Germany. Updated daily from ClinicalTrials.gov.


Transthyretin Amyloid Cardiomyopathy Trials at a Glance

11 actively recruiting trials for transthyretin amyloid cardiomyopathy are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Not Applicable with 1 trial, with the heaviest enrollment activity in Bruges, Groningen, and Berlin. Lead sponsors running transthyretin amyloid cardiomyopathy studies include Bayer, Novo Nordisk A/S, and Steen Hvitfeldt Poulsen.

Browse transthyretin amyloid cardiomyopathy trials by phase

Treatments under study

About Transthyretin Amyloid Cardiomyopathy Clinical Trials

Looking for clinical trials for Transthyretin Amyloid Cardiomyopathy? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Transthyretin Amyloid Cardiomyopathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Transthyretin Amyloid Cardiomyopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 4

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

Transthyretin Amyloid Cardiomyopathy
Bayer50 enrolled10 locationsNCT07298044
Recruiting
Phase 3

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S1,280 enrolled290 locationsNCT07207811
Recruiting

A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany

ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Pfizer1 enrolled1 locationNCT07494656
Recruiting
Phase 1

A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis.

Transthyretin Amyloid Cardiomyopathy
Novo Nordisk A/S14 enrolled1 locationNCT07448623
Recruiting

A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting

Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Bayer2,000 enrolled1 locationNCT07235462
Recruiting

US Benchmarking Clinical Study

Cardiac AmyloidosisHFpEF - Heart Failure With Preserved Ejection FractionHFmrEF+2 more
eMyosound SAS150 enrolled3 locationsNCT07215715
Recruiting

Phenotyping and Characterization of wtATTR-CM (TRACE 1)

Quality of LifeTransthyretin Amyloid CardiomyopathyTransthyretin Amyloidosis+1 more
Steen Hvitfeldt Poulsen120 enrolled1 locationNCT06291805
Recruiting

Thailand ATTR-CM Registry

Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Mahidol University105 enrolled8 locationsNCT06338696
Recruiting

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

Myasthenia GravisAmyloidosisAlpha-Thalassemia+14 more
xCures1,000 enrolled1 locationNCT06539169
Recruiting

Early Diagnosis of Age-Linked CArdiac TransThyRetin Amyloidosis by Selective Screening in Spinal Stenosis Surgery

Transthyretin Amyloid Cardiomyopathy
Philippe Debonnaire400 enrolled1 locationNCT06101108
Recruiting
Not Applicable

Dobutamine Stress Echocardiography in LF/LG Aortic Stenosis and Wild-type Transthyretin Amyloid Cardiomyopathy

Transthyretin Amyloid CardiomyopathyAortic Stenosis
Steen Hvitfeldt Poulsen24 enrolled1 locationNCT06372301